The DOI matches its Crossref record.
Activation interferes with the APO-1 pathway in mature human T cells
Abstract
One of the mechanisms to terminate a specific immune response may involve elimination of antigen activated T cells by programmed cell death, apoptosis. Apoptosis in activated T cells may be induced via the TCR-CD3 complex or/and cell surface molecules like the APO-1 (Fas) antigen, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily. To investigate apoptosis in activated T cells we studied expression of APO-1 and sensitivity to APO-1 mediated apoptosis in human peripheral T lymphocytes. APO-1 is not expressed on cord blood and the majority of resting T cells, but on activated T cells. One day activated T cells in culture showed activation induced resistance to apoptosis (ARA). However, after prolonged in vitro culture, 6 day activated T cells acquired sensitivity to activation induced sensitivity to apoptosis (ASA). Restimulation of the ASA+ activated T cells by triggering TCR-CD3 or CD2 induced proliferation and apoptosis in a fraction of the cells. In the surviving fraction of ASA+ activated T cells, however, this treatment reinduced a transient ARA+ phenotype. Thus, activation of resting mature T cells or restimulation of activated T cells may induce a transient resistance to apoptotic signals. Activation signals may interfere with the APO-1 pathway and may prevent elimination of activated T cells in the periphery (peripheral selection).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Nagata, S., & Golstein, P. (1995) · Science · doi:10.1126/science.7533326 · Cited by 3,979
Inhibition of death receptor signals by cellular FLIP
Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J.-L., Schröter, M., Burns, K., Mattmann, C., et al. (1997) · Nature · doi:10.1038/40657 · Cited by 2,563
Holler, N., Zaru, R., Micheau, O., Thome, M., Attinger, A., Valitutti, S., Bodmer, J.-L., Schneider, P., Seed, B., & Tschopp, J. (2000) · Nature Immunology · doi:10.1038/82732 · Cited by 1,938
CD95's deadly mission in the immune system
Krammer, P. H. (2000) · Nature · doi:10.1038/35037728 · Cited by 1,717
Self-citationAutocrine T-cell suicide mediated by APO-1/(Fas/CD95)
Dhein, J., Walczak, H., Bäumler, C., Debatin, K.-M., & Krammer, P. H. (1995) · Nature · doi:10.1038/373438a0 · Cited by 1,609
Self-citationGeneralized lymphoproliferative disease in mice, caused by a point mutation in the fas ligand
Takahashi, T., Tanaka, M., Brannan, C. I., Jenkins, N. A., Copeland, N. G., Suda, T., & Nagata, S. (1994) · Cell · doi:10.1016/0092-8674(94)90375-1 · Cited by 1,528
Mutations in Fas Associated with Human Lymphoproliferative Syndrome and Autoimmunity
Rieux-Laucat, F., Le Deist, F., Hivroz, C., Roberts, I. A. G., Debatin, K. M., Fischer, A., & de Villartay, J. P. (1995) · Science · doi:10.1126/science.7539157 · Cited by 1,297
Self-citationCD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL
Boise, L. H., Minn, A. J., Noel, P. J., June, C. H., Accavitti, M. A., Lindsten, T., & Thompson, C. B. (1995) · Immunity · doi:10.1016/1074-7613(95)90161-2 · Cited by 1,210
Friesen, C., Herr, I., Krammer, P. H., & Debatin, K.-M. (1996) · Nature Medicine · doi:10.1038/nm0596-574 · Cited by 974
Self-citationStanger, B. Z., Leder, P., Lee, T.-H., Kim, E., & Seed, B. (1995) · Cell · doi:10.1016/0092-8674(95)90072-1 · Cited by 971
The Role of c-FLIP in Modulation of CD95-induced Apoptosis
Scaffidi, C., Schmitz, I., Krammer, P. H., & Peter, M. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.3.1541 · Cited by 819
Self-citationFAP-1: A Protein Tyrosine Phosphatase That Associates with Fas
Sato, T., Irie, S., Kitada, S., & Reed, J. C. (1995) · Science · doi:10.1126/science.7536343 · Cited by 683
The CD95 (APO-1/Fas) and the TRAIL (APO-2L) Apoptosis Systems
Walczak, H., & Krammer, P. H. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4840 · Cited by 628
Self-citationDifferential Modulation of Apoptosis Sensitivity in CD95 Type I and Type II Cells
Scaffidi, C., Schmitz, I., Zha, J., Korsmeyer, S. J., Krammer, P. H., & Peter, M. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.32.22532 · Cited by 580
Self-citationFas and FasL in the homeostatic regulation of immune responses
Lynch, D. H., Ramsdell, F., & Alderson, M. R. (1995) · Immunology Today · doi:10.1016/0167-5699(95)80079-4 · Cited by 558
Newton, K. (1998) · The EMBO Journal · doi:10.1093/emboj/17.3.706 · Cited by 499
The Role of Fas in Autoimmune Diabetes
Chervonsky, A. V., Wang, Y., Wong, F. S., Visintin, I., Flavell, R. A., Janeway, C. A., & Matis, L. A. (1997) · Cell · doi:10.1016/s0092-8674(00)80178-6 · Cited by 496
Immune escape of tumors: apoptosis resistance and tumor counterattack
Igney, F. H., & Krammer, P. H. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.6.907 · Cited by 468
Self-citationFournel, S., Aguerre-Girr, M., Huc, X., Lenfant, F., Alam, A., Toubert, A., Bensussan, A., & Le Bouteiller, P. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6100 · Cited by 463
Caspase Activation Is Required for T Cell Proliferation
Kennedy, N. J., Kataoka, T., Tschopp, J., & Budd, R. C. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.12.1891 · Cited by 459
CD95(APO-1/Fas)-Mediated Apoptosis: Live and Let Die
Krammer, P. H. (1998) · Advances in Immunology · doi:10.1016/s0065-2776(08)60402-2 · Cited by 394
Self-citationFas ligation induces apoptosis of CD40-activated human B lymphocytes.
Garrone, P., Neidhardt, E. M., Garcia, E., Galibert, L., van Kooten, C., & Banchereau, J. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.5.1265 · Cited by 390
Allison, J., Georgiou, H. M., Strasser, A., & Vaux, D. L. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3943 · Cited by 366
Weller, M., Frei, K., Groscurth, P., Krammer, P. H., Yonekawa, Y., & Fontana, A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117462 · Cited by 345
Self-citationThe molecular profile of microglia under the influence of glioma
Li, W., & Graeber, M. B. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos116 · Cited by 340
Fas and Fas Ligand: A Death Factor and Its Receptor
Nagata, S. (1994) · Advances in Immunology · doi:10.1016/s0065-2776(08)60672-0 · Cited by 338
Nitric Oxide Inhibits Fas-induced Apoptosis
Mannick, J. B., Miao, X. Q., & Stamler, J. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.39.24125 · Cited by 315
Regulation of apoptosis in the immune system
Krammer, P. H., Behrmann, I., Daniel, P., Dhein, J., & Debatin, K.-M. (1994) · Current Opinion in Immunology · doi:10.1016/0952-7915(94)90102-3 · Cited by 308
Self-citationMöller, P., Koretz, K., Leithäuser, F., Brüderlein, S., Henne, C., Quentmeier, A., & Krammer, P. H. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910570314 · Cited by 306
Self-citationSytwu, H.-K., Liblau, R. S., & McDevitt, H. O. (1996) · Immunity · doi:10.1016/s1074-7613(00)80306-4 · Cited by 305
Schulze-Osthoff, K., Krammer, P. H., & Dröge, W. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06780.x · Cited by 303
Self-citationActivation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-xL
Huang, D. C. S., Hahne, M., Schroeter, M., Frei, K., Fontana, A., Villunger, A., Newton, K., Tschopp, J., & Strasser, A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14871 · Cited by 297
Cifone, M. G., Roncaioli, P., De Maria, R., Camarda, G., Santoni, A., Ruberti, G., & Testi, R. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00274.x · Cited by 290
Autoimmune thyroid disease: new models of cell death in autoimmunity
Stassi, G., & De Maria, R. (2002) · Nature Reviews Immunology · doi:10.1038/nri750 · Cited by 284
c-FLIPR, a New Regulator of Death Receptor-induced Apoptosis
Golks, A., Brenner, D., Fritsch, C., Krammer, P. H., & Lavrik, I. N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414425200 · Cited by 282
Self-citationActivation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis
Herr, I. (1997) · The EMBO Journal · doi:10.1093/emboj/16.20.6200 · Cited by 278
Estaquier, J., Idziorek, T., Zou, W., Emilie, D., Farber, C. M., Bourez, J. M., & Ameisen, J. C. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.6.1759 · Cited by 273
TRAIL/Apo-2-ligand-induced apoptosis in human T cells
Jeremias, I., Herr, I., Boehler, T., & Debatin, K.-M. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199801)28:01<143::aid-immu143>3.0.co;2-3 · Cited by 267
Self-citationT Cells Deficient in Inositol 1,4,5-Trisphosphate Receptor Are Resistant to Apoptosis
Jayaraman, T., & Marks, A. R. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.6.3005 · Cited by 257
Tumor counterattack: Fact or fiction?
Igney, F. H., & Krammer, P. H. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-005-0680-7 · Cited by 98
Self-citationDeath by neglect as a deletional mechanism of peripheral tolerance
Bertolino, P., Trescol-Biémont, M.-C., Thomas, J., de St Groth, B. F., Pihlgren, M., Marvel, J., & Rabourdin-Combe, C. (1999) · International Immunology · doi:10.1093/intimm/11.8.1225 · Cited by 96
Carney, E. F., Srinivasan, V., Moss, P. A., & Taylor, A. M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101909 · Cited by 26
Metadata
- Authors
- Klas, C., Debatin, K.-M., Jonker, R. R., & Krammer, P. H.
- Venue
- International Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1993
- Volume
- 5
- Issue
- 6
- Pages
- 625-630
- ISSN
- 0953-8178 (ISSN-L)
- 1460-2377
- OpenAlex
- W2097106158
- Cited by
- 447
- References
- 0
- FWCI
- 12.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.